The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 643-652

  Li, Wei ^a,b,c,d   Zhang, Li ^a   Zhang, Ge ^a   Wei, Huafeng ^a,b,c,d   Zhao, Mengxin ^d   Li, Huafei ^a   Guo, Shangjing ^d   Gao, Jie ^a,b   Kou, Geng ^a,b,c,d   Li, Bohua ^a,b,c,d   Dai, Jianxin ^a,b,c,d   Wang, Hao ^a,b,c,d   Guo, Yajun ^a,b,c,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Key Laboratory of Complex Prescription   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d LIAOCHENG UNIVERSITY   (China)

Author keywords

Antibody decoration; Cancer vaccine; Drug delivery system; Immune escaping; Immunotherapy; Nanocarrier's engineering

Indexed keywords

ARGINASE; CANCER VACCINE; CARBON NANOTUBE; COLONY STIMULATING FACTOR 1; CYCLIN D1; CYCLOOXYGENASE 2; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MELAN A; MONOPHENOL MONOOXYGENASE; NANOCARRIER; NANOPARTICLE; PROSTAGLANDIN E2; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNINDEXED DRUG; WART VIRUS VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CHILL; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DIZZINESS; FEVER; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NAUSEA AND VOMITING; NONHUMAN; RASH; SWELLING; VIRUS LIKE AGENT;

ANTIGENS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; NANOSTRUCTURES; NEOPLASMS; POLYMERS;

EID: 84877834157     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313050003     Document Type: Article

References (70)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society, 2012, 1-64.
2. Li, W.; Feng, S.; Guo, Y. Tailoring polymeric micelles to optimize delivery to solid tumors. Nanomedicine (Lond), 2012, 7(8), 1235-1252.
3. Li, W.; Feng, S. S.; Guo, Y. Block copolymer micelles for nanomedicine. Nanomedicine (Lond), 2012, 7(2), 169-172.
4. Li, W.; Zhao, H.; Qian, W.; Li, H.; Zhang, L.; Ye, Z.; Zhang, G.; Xia, M.; Li, J.; Gao, J.; Li, B.; Kou, G.; Dai, J.; Wang, H.; Guo, Y. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials, 2012, 33 (21), 5349-5362.
5. Lesterhuis, W. J.; Haanen, J. B.; Punt, C. J. Cancer immunotherapy-revisited. Nat. Rev. Drug. Discov, 2011, 10(8), 591-600.
6. Sheng, W. Y.; Huang, L. Cancer immunotherapy and nanomedicine. Pharm. Res., 2011, 28(2), 200-214.
7. Bolhassani, A.; Safaiyan, S.; Rafati, S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer, 2011, 10, 3.
8. Dillman, R. O., Schiltz, P.; DePriest, C.; Barth, N.; Beutel, L.; de Leon, C.; O'Connor, A.; Nayak, S. Cancer immunotherapy. Cancer Biother Radiopharm, 2011, 26(1), 1-64.
9. Carstens, M. G. Opportunities and challenges in vaccine delivery. Eur. J. Pharm. Sci., 2009, 36 (4-5), 605-608.
10. Young, K. R.; McBurney, S. P.; Karkhanis, L. U.; Ross, T. M. Virus-like particles: designing an effective AIDS vaccine. Methods, 2006, 40(1), 98-117.
11. Michel, M. L.; Tiollais, P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol. Biol. (Paris). 2010, 58 (4), 288-295.
12. Hamdy, S.; Haddadi, A.; Hung, R.W.; Lavasanifar, A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug. Deliv. Rev., 2011, 63(10-11), 943-955.
13. Roldao, A.; Mellado, M.C.; Castilho, L.R.; Carrondo, M.J.; Alves, P.M. Virus-like particles in vaccine development. Expert. Rev. Vaccines, 2010, 9(10), 1149-1176.
14. Noad, R.; Roy, P. Virus-like particles as immunogens. Trends Microbiol., 2003, 11(9), 438-444.
15. Rodriguez-Limas, W.A.; Tyo, K.E.; Nielsen, J.; Ramirez, O.T.; Palomares, L.A. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb. Cell Fact, 2011, 10, 33.
16. Kasturi, S.P.; Skountzou, I.; Albrecht, R.A.; Koutsonanos, D.; Hua, T.; Nakaya, H.I.; Ravindran, R.; Stewart, S.; Alam, M.; Kwissa, M.; Villinger, F.; Murthy, N.; Steel, J.; Jacob, J.; Hogan, R.J.; Garcia-Sastre, A.; Compans, R.; Pulendran, B. Programming the magnitude and persistence of antibody responses with innate immunity. Nature, 2011, 470(7335), 543-547.
17. Beers, S.A.; Chan, C.H.; French, R.R.; Cragg, M.S.; Glennie, M.J. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol., 2010, 47 (2), 107-114.
18. Herber, D.L.; Cao, W.; Nefedova, Y.; Novitskiy, S.V.; Nagaraj, S.; Tyurin, V.A.; Corzo, A.; Cho, H.I.; Celis, E.; Lennox, B.; Knight, S.C.; Padhya, T.; McCaffrey, T.V.; McCaffrey, J.C.; Antonia, S.; Fishman, M.; Ferris, R.L.; Kagan, V.E.; Gabrilovich, D.I. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med., 2010, 16 (8), 880-886.
19. Ali, O.A.; Huebsch, N.; Cao, L.; Dranoff, G.; Mooney, D.J. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater., 2009, 8 (2), 151-158.
20. Singh, M.; Chakrapani, A.; O'Hagan, D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines, 2007, 6 (5), 797-808.
21. Chen, W.; Yan, W.; Huang, L.A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother., 2008, 57 (4), 517-530.
22. Mesa, C.; Fernandez, L.E. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol., 2004, 82 (6), 644-650.
23. Finn, O.J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol., 2003, 3 (8), 630-641.
24. Oyewumi, M.O.; Kumar, A.; Cui, Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines, 2010, 9 (9), 1095-1107.
25. Dunn G.P.; Bruce A.T.; Ikeda H.; Old L.J.; Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002, 3(11), 991-998.
26. Ganss, R.; Hanahan, D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res., 1998, 58 (20), 4673-4681.
27. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 2005, 5 (4), 263-274.
28. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol., 2006, 6 (4), 295-307.
29. Williams, L.M.; Rudensky, A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol., 2007, 8 (3), 277-284.
30. Jackson, C.; Ruzevick, J.; Phallen, J.; Belcaid, Z.; Lim, M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol., 2011, 2011, 732413.
31. Ding, B.; Wu, X.; Fan, W.; Wu, Z.; Gao, J.; Zhang, W.; Ma, L.; Xiang, W.; Zhu, Q.; Liu, J.; Ding, X.; Gao, S. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignantmelanoma: target formulation development and in vitro anticancer activity. Int. J. Nanomedicine, 2011, 6, 1991-2005.
32. Li, W.; Li, H.; Li, J.; Wang, H.; Zhao, H.; Zhang, L.; Xia, Y.; Ye, Z.; Gao, J.; Dai, J.; Guo, Y. Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. Int. J. Nanomedicine, 2012, 7, 4661-4677.
33. Garcea, R.L.; Gissmann, L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr. Opin. Biotechnol., 2004, 15 (6), 513-517.
34. Ludwig, C.; Wagner, R. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol., 2007, 18 (6), 537-545.
35. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 2004, 10 (9), 909-915.
36. Kirnbauer, R.; Booy, F.; Cheng, N.; Lowy, D.R.; Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A., 1992, 89 (24), 12180-12184.
37. Mellado, M. C.; Mena, J. A.; Lopes, A.; Ramirez, O. T.; Carrondo, M. J.; Palomares, L. A.; Alves, P. M. Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnol. Bioeng., 2009, 104 (4), 674-686.
38. Zolnik, B.S.; Gonzalez-Fernandez, A.; Sadrieh, N.; Dobrovolskaia, M.A. Nanoparticles and the immune system. Endocrinology, 2010, 151 (2), 458-465.
39. Klippstein, R.; Pozo, D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine, 2010, 6 (4), 523-529.
40. Li, W.; Guo, Q.; Zhao, H.; Zhang, L.; Li, J.; Gao, J.; Qian, W.; Li, B.; Chen, H.; Wang, H.; Dai, J.; Guo, Y. Novel dual-control poly(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug release. Nanomedicine (Lond), 2012, 7 (3), 383-392.
41. Hubbell, J.A.; Thomas, S.N.; Swartz, M. A. Materials engineering for immunomodulation. Nature, 2009, 462 (7272), 449-460.
42. Champion, J.A.; Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A., 2006, 103 (13), 4930-4934.
43. Champion, J.A.; Walker, A.; Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res., 2008, 25 (8), 1815-1821.
44. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS. J, 2007, 9 (2), E128-147.
45. Elamanchili, P.; Diwan, M.; Cao, M.; Samuel, J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine, 2004, 22 (19), 2406-2412.
46. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol, 2007, 2 (12), 751-760.
47. Moon, J.J.; Suh, H.; Bershteyn, A.; Stephan, M.T.; Liu, H.; Huang, B.; Sohail, M.; Luo, S.; Um, S.H.; Khant, H.; Goodwin, J.T.; Ramos, J.; Chiu, W.; Irvine, D.J. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater, 2011, 10 (3), 243-251.
48. Lu, Y.; Sega, E.; Leamon, C.P.; Low, P.S. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Deliv. Rev., 2004, 56 (8), 1161-1176.
49. Peer, D.; Park, E.J.; Morishita, Y.; Carman, C.V.; Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, 2008, 319 (5863), 627-630.
50. Poland, C.A.; Duffin, R.; Kinloch, I.; Maynard, A.; Wallace, W.A.; Seaton, A.; Stone, V.; Brown, S.; Macnee, W.; Donaldson, K. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol, 2008, 3 (7), 423-428.
51. Witzmann, F.A.; Monteiro-Riviere, N.A. Multi-walled carbon nanotube exposure alters protein expression in human keratinocytes. Nanomedicine, 2006, 2 (3), 158-168.
52. Aggarwal, P.; Hall, J.B.; McLeland, C.B.; Dobrovolskaia, M.A.; McNeil, S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev., 2009, 61 (6), 428-437.
53. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 2008, 5 (4), 487-495.
54. Dobrovolskaia, M.A.; McNeil, S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol., 2007, 2 (8), 469-478.
55. Moghimi, S.M. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta., 2002, 1590 (1-3), 131-139.
56. Boudier, A.; Aubert-Pouessel, A.; Louis-Plence, P.; Gerardin, C.; Jorgensen, C.; Devoisselle, J.M.; Begu, S. The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials, 2009, 30 (2), 233-241.
57. Roy, P.; Noad, R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin., 2008, 4 (1), 5-12.
58. Liu, Z.; Winters, M.; Holodniy, M.; Dai, H. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew. Chem. Int. Ed. Engl., 2007, 46 (12), 2023-2027.
59. Basarkar, A.; Singh, J. Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm. Res., 2009, 26 (1), 72-81.
60. Li, W.; Nakayama, M.; Akimoto, J.; Okano, T. Effect of block compositions of amphiphilic block copolymers on the physicochemical properties of polymeric micelles. Polymer, 2011, 52 (17), 3783-3790.
61. Li, W.; Li, J.; Gao, J.; Li, B.; Xia, Y.; Meng, Y.; Yu, Y.; Chen, H.; Dai, J.; Wang, H.; Guo, Y. The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials, 2011, 32 (15), 3832-3844.
62. Li, W.; Hong, L.; Ngai, T.; Huang, H.; He, T.; Wu, C.A comparative study of chain dynamics of di-and tri-block copolymers in semidilute solution in a non-selective solvent. Chin. J. Polym. Sci., 2004, 22 (6), 589-598.
63. Odian, G., Principles of polymerization. Wiley-Interscience: 2004.
64. Lee, E.S.; Na, K.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett., 2005, 5 (2), 325-329.
65. Takae, S.; Miyata, K.; Oba, M.; Ishii, T.; Nishiyama, N.; Itaka, K.; Yamasaki, Y.; Koyama, H.; Kataoka, K. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J. Am. Chem. Soc., 2008, 130 (18), 6001-6009.
66. Tai, W.; Mahato, R.; Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release, 2010, 146 (3), 264-275.
67. Zhang, Z.; Tongchusak, S.; Mizukami, Y.; Kang, Y.J.; Ioji, T.; Touma, M.; Reinhold, B.; Keskin, D.B.; Reinherz, E.L.; Sasada, T. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials, 2011, 32 (14), 3666-3678.
68. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7 (9), 771-782.
69. Nochi, T.; Yuki, Y.; Takahashi, H.; Sawada, S.; Mejima, M.; Kohda, T.; Harada, N.; Kong, I.G.; Sato, A.; Kataoka, N.; Tokuhara, D.; Kurokawa, S.; Takahashi, Y.; Tsukada, H.; Kozaki, S.; Akiyoshi, K.; Kiyono, H. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat.Mater, 2010, 9 (7), 572-578.
70. Vyas, S.P.; Gupta, P.N. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines, 2007, 6 (3), 401-418.